Sanjivani Parenteral Ltd, a core pharmaceutical company certified by WHO-GMP, is a trailblazer in the production of injectables and oral solids, boasting over two-and-a-half decades of extensive experience. The company's primary focus is on life-saving medications, with exports to more than 25 countries and serving a vast geographical area through two WHO-GMP certified manufacturing facilities located in Mumbai and Dehradun. Established as a public limited company in October 1994, Sanjivani Parenteral was co-founded by Anami H Khemka and a team of industry professionals. Engaged in the manufacturing of pharmaceutical drugs, the company's product portfolio includes oral solids, small volume parenteral solutions, and sterile powder formulations.
Sanjivani Parenteral is in the process of establishing a new plant in Taloja, Maharashtra, dedicated to the production of high-grade antibiotics and life-saving injectables for various infections, pre- and post-operative care. The planned capacities for its products include 150 lac pa for liquid vials, 150 lac pa for powder vials, and 73 lac pa for ampoules, resulting in a total capacity of 375 lac pa. To finance this project, the company conducted a public issue in January 1996. Notably, prominent pharmaceutical companies such as Merind, Lupin Laboratories, and USV have expressed interest in procuring the company's liquid vials and ampules for the first year's production.
In 1998-99, Sanjivani Parenteral obtained the WHO GMP Certificate, paving the way for potential exports to Africa, Europe, and Latin America. The company has also collaborated with Cadila Ltd., Alkem Ltd., and Indian Immunologicals Ltd. for marketing its products. Additionally, in 1999-2000, Sanjivani Parenteral forged a partnership with Ranbaxy, India's leading pharmaceutical giant, for the manufacturing of its products. In 2009, the company expanded its operations by acquiring a new pharmaceutical manufacturing plant in Uttarakhand.
Sanjivani Parenteral is in the process of establishing a new plant in Taloja, Maharashtra, dedicated to the production of high-grade antibiotics and life-saving injectables for various infections, pre- and post-operative care. The planned capacities for its products include 150 lac pa for liquid vials, 150 lac pa for powder vials, and 73 lac pa for ampoules, resulting in a total capacity of 375 lac pa. To finance this project, the company conducted a public issue in January 1996. Notably, prominent pharmaceutical companies such as Merind, Lupin Laboratories, and USV have expressed interest in procuring the company's liquid vials and ampules for the first year's production.
In 1998-99, Sanjivani Parenteral obtained the WHO GMP Certificate, paving the way for potential exports to Africa, Europe, and Latin America. The company has also collaborated with Cadila Ltd., Alkem Ltd., and Indian Immunologicals Ltd. for marketing its products. Additionally, in 1999-2000, Sanjivani Parenteral forged a partnership with Ranbaxy, India's leading pharmaceutical giant, for the manufacturing of its products. In 2009, the company expanded its operations by acquiring a new pharmaceutical manufacturing plant in Uttarakhand.
